Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout
Research output: Contribution to journal › Article › peer-review
Electronic versions
(ICER) of £44,954 per QALY gained. The probability of testing being cost-effective at a threshold of £30,000 per QALY was 0.25. Reduced costs of testing or febuxostat resulted in an ICER below £30,000 per QALY gained. The ICER for patients with chronic renal insufficiency was £38,478 per QALY gained.
Conclusion: Routine testing for HLA-B*58:01 in order to reduce the incidence of adverse drug reactions in patients being prescribed allopurinol for gout is unlikely to be cost-effective in the UK; however testing is expected to become cost-effective with reductions in the cost of genotyping, and with the future availability of cheaper, generic febuxostat.
Conclusion: Routine testing for HLA-B*58:01 in order to reduce the incidence of adverse drug reactions in patients being prescribed allopurinol for gout is unlikely to be cost-effective in the UK; however testing is expected to become cost-effective with reductions in the cost of genotyping, and with the future availability of cheaper, generic febuxostat.
| Original language | English |
|---|---|
| Pages (from-to) | 1729-1739 |
| Journal | Rheumatology |
| Volume | 56 |
| Issue number | 10 |
| Early online date | 14 Jul 2017 |
| DOIs | |
| Publication status | Published - 1 Oct 2017 |
Total downloads
No data available